The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsEffects of levodopa on regional cerebral metabolism and blood flowVascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.Development of histocompatible primate-induced pluripotent stem cells for neural transplantationEvidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsyL-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain.Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.Neuroinflammation in Parkinson's disease.Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's diseaseβ-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.
P2860
Q21129423-44C9BD07-0444-4525-95BC-67C835FEA597Q35040119-663E40A0-0DBA-4639-B201-60DB137B1640Q35163198-E3F41CFF-6B59-42ED-9D3E-42C452456929Q35924439-E1807EF6-AFB2-42E3-A253-3615F2C15BCEQ35960407-8864EAE6-C273-427E-8A61-2A24D8A6573CQ36131925-C4F3A2D1-98B5-4B97-8179-3F1FC2DD73DFQ37001159-641A4FD8-439D-4C30-A931-AF1C23F8CAC4Q37079115-91204C26-C99C-4A92-8059-00EA3010C155Q37179338-28336727-C65F-462D-B27E-42D2BF432897Q37925513-8B8A9484-1A90-47ED-8644-8B4577B978F3Q38469837-DF33C7D7-5581-414B-92FF-CEE632053720Q41814137-4477DB55-6798-4727-AAA4-64E66AAEA107Q48825282-4425738F-6C5E-4448-B2D5-9A5ECCFE0C65Q48956010-D14DCF78-671C-4F8E-9300-F8F8F1D94CBD
P2860
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@ast
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@en
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@nl
type
label
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@ast
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@en
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@nl
prefLabel
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@ast
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@en
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@nl
P2093
P2860
P921
P1476
The blood-brain barrier is int ...... m in vivo neuroimaging studies
@en
P2093
Anna-Liisa Brownell
Arnar Astradsson
Bruce G Jenkins
Jack S McDowell
Ji-Kyung Choi
Michele A Levesque
Ole Isacson
Penelope J Hallett
Roger D Spealman
P2860
P304
P356
10.1016/J.NBD.2009.05.018
P407
P577
2009-09-01T00:00:00Z